KHARTOUM, (Nabaa Sudan) – The National Malaria Control Program has warned against adopting or circulating diagnostic and treatment recommendations issued by entities outside the Federal Ministry of Health, affirming that the National Protocol for Malaria Diagnosis and Treatment, 2023 edition, is the approved and binding reference for health personnel in Sudan.
In a statement, the program said recently circulated recommendations from the U.S. Centers for Disease Control and Prevention (CDC) on malaria diagnosis and treatment contradict the national protocol in force in the country.
It explained that variations in malaria parasite responses to medicines from one country to another mean that treatment recommendations are linked to the epidemiological situation and drug resistance in each country. It noted that the program continuously monitors the efficacy and safety of malaria medicines in cooperation with the World Health Organization (WHO) and academic institutions inside and outside Sudan.
The program said updates to the national protocol are based on the findings of studies and scientific monitoring, while taking into account Sudan’s specific epidemiological and pharmaceutical situation. It noted that any amendment or update will be announced exclusively through the official channels of the Federal Ministry of Health.
The program warned that adopting recommendations issued by entities other than the ministry could lead to clinical practices that contravene the approved protocol, potentially exposing patients to risks and subjecting health practitioners to accountability under the laws and regulations governing health practice.
The program affirmed that the 2023 protocol is the only approved national reference for dealing with malaria cases in Sudan until any official update is issued through the Federal Ministry of Health.
Sudan#Nabaa_Sudan#Nabaa#
